Sector revisions Cytokinetics, Incorporated

Stocks

Market Closed - Nasdaq Other stock markets 21:00:00 17/07/2026 BST			5-day change	1st Jan Change
80.18 ^USD	-0.22%		-5.53%	+26.19%

07-14	Cytokinetics Insider Sold Shares Worth $615,150, According to a Recent SEC Filing	MT
07-07	RBC Capital Adjusts Cytokinetics Price Target to $117 From $119, Maintains Outperform Rating	MT

Sector:

Location:

X axis:

Main competitors

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	1m. Revenue rev.	4m. EPS revision	4m. Revenue rev.	1y. EPS revision	1y. Revenue rev.	Visibility	Nbr of analysts
	CYTOKINETICS, INCORPORATED							20
	ARGENX SE							15
	WUXI APPTEC CO., LTD.							18
	INSMED INCORPORATED							21
	BIONTECH SE							20
	WUXI BIOLOGICS (CAYMAN) INC.							23
	GENMAB A/S							15
	PHARMAESSENTIA CORPORATION							7
	SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.							17
	EXELIXIS, INC.							15
	MADRIGAL PHARMACEUTICALS, INC.							14
	SUMMIT THERAPEUTICS INC.							13
	ARROWHEAD PHARMACEUTICALS, INC.							11
	AKESO, INC.							20
	CRINETICS PHARMACEUTICALS, INC.							10
	VAXCYTE, INC.							9
	REMEGEN CO., LTD.							15
	IMMUNITYBIO, INC.							3
	SHANGHAI ALLIST PHARMACEUTICALS CO., LTD.							-
	Average							15
	Weighted average by Cap.							16